Video

Understanding Treatment Options in Melanoma

Author(s):

Kristie L. Kahl

On behalf of AiM at Melanoma, Drs. Jeffrey Farma and Sunandana Chandra discuss current and future treatment options for melanoma, including a rare subtype.

Related Videos
Dr. Kelly Stratton
Related Content
Image of COVID-19 cells.
November 18th 2024

COVID-19 RNA May Be Linked to Metastatic Cancer Regression

Ashley Chan
RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of a doctor examining a patient's skin.
November 4th 2024

Early Data Show Benefits With Ameluz-Photodynamic Therapy in Skin Cancer Subset

Darlene Dobkowski, MA
Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in early data from a phase 3 trial.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Illustration of a person with breast cancer.
October 11th 2024

‘The Office’ Actress Opens Up About Breast Cancer, Martha Davis Cancels Concerts After Radiation and More

Alex Biese Ashley Chan
From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.
Illustration of a DNA strand, generated by Adobe Firefly.
October 8th 2024

ctDNA Testing Helps Predict Recurrence in Merkel Cell Carcinoma

Ashley Chan
Among patients with Merkel cell carcinoma, using ctDNA testing may help with watching the disease for potential recurrences and those who are high-risk.